GAA
GSK icon

Green Alpha Advisors’s GSK GSK Stock Holding History

Green Alpha Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27,316
Closed -$924K – 127
2024
Q4 		$924K Buy
27,316
+4,107
+18% +$148K 0.74% 50
2024
Q3 		$949K Sell
23,209
-735
-3% -$30.1K 0.75% 45
2024
Q2 		$922K Sell
23,944
-1,551
-6% -$65.2K 0.74% 49
2024
Q1 		$1.09M Buy
25,495
+7,710
+43% +$318K 0.79% 46
2023
Q4 		$659K Sell
17,785
-5,728
-24% -$206K 0.48% 87
2023
Q3 		$852K Buy
23,513
+2,422
+11% +$86K 0.65% 58
2023
Q2 		$752K Buy
21,091
+2,723
+15% +$97.7K 0.49% 78
2023
Q1 		$654K Buy
18,368
+3,016
+20% +$106K 0.46% 84
2022
Q4 		$539K Buy
15,352
+2,844
+23% +$94.7K 0.45% 88
2022
Q3 		$368K Sell
12,508
-48,928
-80% -$1.85M 0.31% 119
2022
Q2 		$3.34M Buy
+61,436
New +$3.39M 0.77% 39

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Green Alpha Advisors's GSK Position: Q1 2025 in Review

Green Alpha Advisors sold out of GSK (GSK) in Q1 2025, closing a stake of 27,316 shares — an estimated $924K sold.

Green Alpha Advisors first reported a position in GSK in Q2 2022 and held it in 11 quarters. The position peaked at $3.34M in Q2 2022. 857 funds tracked by Wall St. Rank hold GSK as of Q1 2025.

  • Green Alpha Advisors reported no remaining GSK position as of Q1 2025 after selling out during the quarter.
  • Green Alpha Advisors sold 27,316 GSK shares in Q1 2025, an estimated $924K.
  • Green Alpha Advisors first reported a position in GSK in Q2 2022 and held it in 11 quarters.
  • Green Alpha Advisors's GSK position peaked at $3.34M in Q2 2022.
  • 857 funds tracked by Wall St. Rank held GSK as of Q1 2025.

Based on Green Alpha Advisors's 13F filing for Q1 2025, filed 9 Apr 2025.